Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pharmaceutical products. Its product portfolio and product candidates include AzaSite, a topical anti-infective product candidate in phase III clinical trials for the treatment of bacterial conjunctivitis, as well as other potential topical anti-infective products containing azithromycin for use in the treatment of human ocular or ophthalmic indications; Prolacria (diquafosol tetrasodium), which is in phase III clinical trials for the treatment of dry eye disease; and Bilastine, a non-sedating oral H1-antihistamine compound in phase III clinical trials...